Diclofenac Reverse-Switched In Norway As Risks Outweigh Benefits
Norway becomes the latest country to reverse-switch diclofenac in response to a 2018 study linking low doses of the drug to cardiovascular adverse events.
You may also be interested in...
OTC presentations of ranitidine have been pulled from shelves in Denmark, Finland and Norway after the European Medicines Agency launched a review into the drug over safety fears.
Norway's move to encourage more innovative Rx-to-OTC switches has begun to bear fruit with the recent reclassification of Pfizer's Viagra. The country's decision to introduce a new non-prescription drug category to promote switching can be used as a model for securing a new wave of more complex switches elsewhere around the world.
Pfizer has taken the first steps towards turning its Viagra erectile dysfunction treatment into a pan-European OTC brand by taking advantage of Norway's new "non-prescription medicines with guidance" category to secure the Rx-to-OTC switch of the product. Norway will be the second European market where Viagra is available OTC after the UK switched the drug in 2017.